Search
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368InvestigationalAnti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalIt antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.
ECT-001 expanded cord blood
go.drugbank.com/drugs/DB21745Investigational[L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.
TA-NIC
go.drugbank.com/drugs/DB05445InvestigationalTA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis
BBIBP-CorV
go.drugbank.com/drugs/DB15807InvestigationalAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Arsthinol
go.drugbank.com/drugs/DB08928ExperimentalConsidered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalEperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and
Calcimycin
go.drugbank.com/drugs/DB19408InvestigationalPrimarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi.
Docirbrutinib
go.drugbank.com/drugs/DB21606InvestigationalDocirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma).